Agilent Technologies, Inc.
A- Exchange
- NYSE
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001090872
In the last 90 days, Agilent Technologies, Inc. insiders filed 0 open-market purchases and 1 sale; 1,135 institutions reported holding it in 13F filings for Q2 2026, worth $34.6B in total; Greenhaven Associates is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Agilent Technologies, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 940
- −42 vs. Q1 2023
- Shares held
- 256.7M
- −3.87M (−1.5%) vs. Q1 2023
- Total value
- $30.9B
- −$5.26B (−14.5%) vs. Q1 2023
- New holders
- 82
- 301 more added
- Sold out
- 124
- 364 more reduced
5 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting A on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,135 | $34.6B |
| Q1 2026 | 1,077 | $28.9B |
| Q4 2025 | 1,149 | $34.9B |
| Q3 2025 | 1,042 | $32.2B |
| Q2 2025 | 1,010 | $30.1B |
| Q1 2025 | 1,023 | $29.6B |
| Q4 2024 | 1,079 | $34.0B |
| Q3 2024 | 1,054 | $37.2B |
| Q2 2024 | 1,013 | $33.0B |
| Q1 2024 | 1,015 | $37.9B |
| Q4 2023 | 1,007 | $35.7B |
| Q3 2023 | 920 | $28.3B |
| Q2 2023 | 940 | $30.9B |
| Q1 2023 | 987 | $36.2B |
| Q4 2022 | 966 | $38.7B |
| Q3 2022 | 898 | $31.3B |
| Q2 2022 | 887 | $30.6B |
| Q1 2022 | 933 | $34.7B |
| Q4 2021 | 984 | $42.0B |
| Q3 2021 | 945 | $41.5B |
| Q2 2021 | 887 | $38.9B |
| Q1 2021 | 874 | $33.2B |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Agilent Technologies, Inc.; share changes are against Q1 2023.